StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
603193.SS$23.45-3.58%
Fair $23.45+0.0%

603193.SS

Runben Biotechnology Co., Ltd.

Consumer Defensive / Household & Personal ProductsShanghai

$23.45

-0.87 (-3.58%)

Fairly Valued+0.0%Fair Value $23.45Fund rank 37/100 · Data gapFallback financials|
SA 49/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $187.4M · quality 76.3/100

Data gap 37/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 78/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

49/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists.
Thesis & Journal · 603193.SSLocal privado en este navegador · Runben Biotechnology Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$9.5B

P/E

29.3x

↑

EV/EBITDA

24.1x

↑

ROE

14.2%

↑

Gross Margin

58.3%

↑

Debt/Equity

0.00

↓
52-Week Range$23
$20$44

TradingView lightweight chart

603193.SS price, volumen y niveles de valoración

Último $23.45Periodo +6.2%
Fair value: $23.45

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+21.7%

FCF CAGR

+14.6%

FCF margin

12.1%

FCF / Net income

0.60x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.54B · net income $314.5M · FCF $187.4M

2022-FY → 2025-FY

Gross margin

58.3%+4.1% pts

Operating margin

21.6%+0.6% pts

Net margin

20.4%+1.7% pts

FCF margin

12.1%-2.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.54B$1.54B$1.32B$1.03B$856.1M
Net Income$314.5M$314.5M$300.2M$226.0M$160.0M
EBITDA$384.4M$384.4M$373.3M$290.1M$208.9M
EPS0.780.780.740.640.47
Gross Margin58.3%58.3%58.2%56.3%54.2%
Operating Margin21.6%21.6%23.6%24.3%21.1%
Net Margin20.4%20.4%22.8%21.9%18.7%
Balance Sheet
Debt/Equity0.000.000.000.000.01
Current Ratio10.9810.98———
Cash Flow
Free Cash Flow$187.4M$187.4M$183.0M$238.9M$124.7M
Returns
ROE14.2%14.2%14.4%11.8%22.1%
Valuation
P/E29.3129.3131.4727.41—
EV/EBITDA24.1224.1225.0320.53—
P/B4.264.264.543.22—
Growth & Yield
Revenue Growth17.2%17.2%27.6%20.7%—
EPS Growth5.4%5.4%15.6%36.2%—
Dividend Yield1.9%1.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

38.7%

muy exigente

EPS terminal req.

$2.08

Spread vs growth

-33.3%

5Y implied EPS CAGR

26.4%

muy exigente

EPS terminal req.

$2.52

Spread vs growth

-21.0%

10Y implied EPS CAGR

17.9%

exigente

EPS terminal req.

$4.05

Spread vs growth

-12.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -41.1%

Total return

-41.1%

Start / end P/E

55.6x → 30.1x

EPS bridge

0.74 → 0.78

Residual

-2.5%

EPS growth+5.4%
Multiple rerating-45.9%
Dividend+1.9%
Residual / FX / buybacks / cross-term-2.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.